Tiny lab test hopes to improve bone grafting for tooth loss

NCT ID NCT04964466

Ongoing Knowledge-focused Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This lab study compares how much growth factor (PDGF-BB) is released over time from two materials used in bone grafting: platelet-rich fibrin (PRF) from a patient's blood and a commercial product called GEM21S. Researchers will mix these with bone substitutes and measure growth factor levels at several time points. Only 5 samples are being tested, so this is early-stage knowledge gathering, not a treatment trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Platelet-rich fibrin (PRF) and recombinant human platelet-derived growth factor-BB (rhPDGF-BB, GEM21S)
What this could lead to: If successful, this could help dentists choose the best way to deliver growth factors for bone healing procedures.
What could go wrong: This is a very small lab experiment with only 5 samples, not a patient trial. Results may not translate to real-world healing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE LOSS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bone Diseases, Metabolic osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BONE LOSS

Contacts and locations

Locations

University of Alabama at Birmingham

Birmingham, Alabama, 35294-0007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.